Patients with HER2-mutated BC have a worse prognosis than those without mutations; in non-small cell lung cancer (NSCLC), patients with HER2 mutations are more sensitive to some HER2-targeted therapeutic agents. This evidence concerns the gene ERBB2 and breast cancer.